TEGRETOL (carbamazepine) by Novartis is cytochrome p450 3a4 inducers [moa]. First approved in 1987.
Drug data last refreshed 3d ago
TEGRETOL (carbamazepine) is an oral suspension small-molecule mood stabilizer approved by the FDA on December 18, 1987, and manufactured by Novartis. It functions as a cytochrome P450 3A4 inducer and is indicated for mood stabilization in psychiatric conditions. The drug represents a foundational therapeutic agent in psychopharmacology with well-established clinical utility, though it now faces significant generic and branded competition in a mature market.
Cytochrome P450 3A4 Inducers
Mood Stabilizer
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
Worked on TEGRETOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZero open career roles are currently linked to TEGRETOL, reflecting its mature, declining commercial stage. Relevant roles in carbamazepine products historically include brand managers defending share against generics, medical science liaisons managing clinician relationships, and sales representatives focused on institutional and specialty channels. Professionals in this space require expertise in generic transition management, formulary negotiation, and cost-effectiveness argumentation rather than primary demand generation.